Please ensure Javascript is enabled for purposes of website accessibility

Why Ocugen Stock Is Tanking Today

By Keith Speights – May 7, 2021 at 11:40AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors didn't get what they wanted in the biotech's Q1 update.

What happened

Shares of Ocugen (OCGN 1.67%) were tanking by 12.7% as of 11:16 a.m. EDT on Friday after falling as much as 20.6% earlier in the day. The big decline came after the company provided its first-quarter update before the market opened today.

So what

Ocugen didn't generate any revenue in the first quarter. The drugmaker posted a net loss of nearly $7.1 million, or $0.04 per share. Only two analysts surveyed by Refinitiv cover the stock. One expected revenue of $156.2 million and earnings of $1.01 per share, while the other analyst projected no revenue and a loss of $0.02 per share. 

Gloved hand holding a vaccine vial with a syringe and needle

Image source: Getty Images.

However, it likely wasn't Ocugen's revenue and earnings misses that concerned investors. Instead, the bigger issue was probably that the company still hasn't made tangible progress toward securing U.S. Emergency Use Authorization (EUA) for COVID-19 vaccine Covaxin. 

Ocugen stated that it's "currently in discussions" with the Food and Drug Administration about Covaxin. But that's what the company has been saying for months.

There was one new development, though. Ocugen said that it has "submitted key information and data to date as a Master File for FDA review prior to a planned EUA application once additional data is received from Bharat Biotech from the ongoing Phase 3 clinical trial."

Now what

It's obvious that the big catalyst the biotech stock needs is for the FDA to indicate that it's open to an EUA filing for Covaxin based on Bharat's clinical studies in India. Expect Ocugen's shares to remain highly volatile until there's more clarity from the agency.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocugen, Inc. Stock Quote
Ocugen, Inc.
$1.82 (1.67%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.